Indivior PLC (LON:INDV)
Market Cap | 963.14M |
Revenue (ttm) | 905.57M |
Net Income (ttm) | -47.99M |
Shares Out | 124.76M |
EPS (ttm) | -0.37 |
PE Ratio | n/a |
Forward PE | 8.19 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 20,380 |
Average Volume | 310,259 |
Open | 786.00 |
Previous Close | 772.00 |
Day's Range | 782.50 - 799.50 |
52-Week Range | 548.71 - 1,485.00 |
Beta | 0.32 |
RSI | 59.11 |
Earnings Date | Apr 25, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
News
A Look at Indivior's Upcoming Earnings Report
Indivior (NASDAQ: INDV) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement. Analysts estimate that Indivior will r...
Decoding Indivior PLC (INDV): A Strategic SWOT Insight
Decoding Indivior PLC (INDV): A Strategic SWOT Insight
Two Seas Capital LP Reduces Stake in Indivior PLC
Two Seas Capital LP Reduces Stake in Indivior PLC

Indivior Announces Further Changes to Board of Directors
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...

UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
Indivior gets FDA approval for label changes for Sublocade injection

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc (NASDAQ: INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations. Addiction and mental illnesses-focused Indivior reported fourth-qua...

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
Indivior PLC 2024 Q4 - Results - Earnings Call Presentation
Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result
Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result

UK's Indivior forecasts 17% decline in 2025 revenue
British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for...
Indivior reports Q4 results

Indivior Announces FY and Q4 2024 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024.
Indivior PLC (INDV) Shares Down 0.83% on Feb 19
Indivior PLC (INDV) Shares Down 0.83% on Feb 19

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes
RICHMOND, Va. , Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative...
Two Seas Capital LP Adjusts Position in Indivior PLC
Two Seas Capital LP Adjusts Position in Indivior PLC

Indivior CFO steps down from board after discussions with Oaktree Capital
Indivior (INDV) stock in focus as CFO resigns from board amid pressure from Oaktree Capital Management. Read more here.

BUSINESS LIVE: Wage growth accelerates; Britvic takeover cleared; Capita to cut more staff
Among the companies with reports and trading updates today are Britvic, Capita, Chemring and Indivior.
Indivior PLC (INDV) Trading 3.1% Higher on Nov 19
Indivior PLC (INDV) Trading 3.1% Higher on Nov 19

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC
SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC